Drug interaction study for COPD inhaler: does cyclosporine change CHF6001 levels?

NCT ID NCT06892756

Completed Knowledge-focused Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 1 study in 30 healthy volunteers looked at how cyclosporine, a drug that blocks certain transporters, affects the amount of CHF6001 (Tanimilast) in the blood. Participants took CHF6001 alone first, then again after taking cyclosporine. The goal was to see if cyclosporine changes CHF6001 levels, which could impact dosing for COPD patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CHF6001 (Tanimilast) dry powder inhaler and oral cyclosporine
What this could lead to: If successful, this study could help doctors understand how to safely combine CHF6001 with other drugs that affect transporters, potentially improving COPD treatment.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. It only measures drug levels, not effectiveness or safety for COPD. Results may not apply to real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Locations

Medical Centre Comac Medical Ltd

Sofia, 1612, Bulgaria

More trials for these conditions

Other studies related to the condition(s) this trial covers.